Thambidurai Ilanchezhian, Prabha S Lakshmi, Nagar Shilpa, Patil Hemkant, Ayyappan S, Periasamy Panneerselvam
Department of Biochemistry, Vinayaka Mission's Medical College and Hospital, Puducherry, India.
Department of Biochemistry, JMF's ACPM Medical College and Hospital, Dhule, Maharashtra, India.
J Pharm Bioallied Sci. 2025 Apr-Jun;17(2):66-68. doi: 10.4103/jpbs.jpbs_1023_25. Epub 2025 Jul 23.
Hyperthyroidism disrupts bone metabolism, leading to increased bone turnover and potential loss of bone mineral density. Sclerostin, a key regulator of bone formation, may serve as a useful biomarker reflecting skeletal changes in thyroid dysfunction.
To evaluate serum sclerostin levels in patients with hyperthyroidism and examine their correlation with thyroid hormone parameters-free triiodothyronine (fT), free thyroxine (fT), and thyroid-stimulating hormone (TSH).
A case-control study was conducted at ACPM Medical College and Hospital, enrolling 30 hyperthyroid patients (including subclinical cases) and 30 age- and sex-matched healthy controls. Serum levels of sclerostin and thyroid hormones were measured using electrochemiluminescence immunoassay. Analysis of variance was used to compare sclerostin levels between groups, and Pearson correlation analysis assessed relationships between sclerostin and thyroid hormones.
Hyperthyroid patients exhibited lower mean serum sclerostin levels (1.2 ng/mL) compared to healthy controls (1.5 ng/mL), although the difference was not statistically significant ( = 0.48). Sclerostin showed a significant negative correlation with fT₃ ( = -0.45, < 0.001) and fT₄ ( = -0.38, = 0.002), and a positive correlation with TSH ( = 0.50, < 0.001).
Serum sclerostin levels are significantly associated with thyroid hormone status in hyperthyroid individuals. These findings suggest that sclerostin may serve as a potential biomarker for monitoring bone health in thyroid dysfunction. Further large-scale, longitudinal studies are warranted to confirm its diagnostic and prognostic utility.
甲状腺功能亢进会扰乱骨代谢，导致骨转换增加以及骨矿物质密度潜在丢失。硬化素是骨形成的关键调节因子，可能作为反映甲状腺功能障碍时骨骼变化的有用生物标志物。
评估甲状腺功能亢进患者的血清硬化素水平，并检查其与甲状腺激素参数——游离三碘甲状腺原氨酸（fT₃）、游离甲状腺素（fT₄）和促甲状腺激素（TSH）的相关性。
在ACPM医学院及医院进行了一项病例对照研究，纳入30例甲状腺功能亢进患者（包括亚临床病例）和30例年龄及性别匹配的健康对照。采用电化学发光免疫分析法测定血清硬化素和甲状腺激素水平。方差分析用于比较组间硬化素水平，Pearson相关分析评估硬化素与甲状腺激素之间的关系。
与健康对照（1.5 ng/mL）相比，甲状腺功能亢进患者的平均血清硬化素水平较低（1.2 ng/mL），尽管差异无统计学意义（P = 0.48）。硬化素与fT₃（r = -0.45，P < 0.001）和fT₄（r = -0.38，P = 0.002）呈显著负相关，与TSH呈正相关（r = 0.50，P < 0.001）。
血清硬化素水平与甲状腺功能亢进个体的甲状腺激素状态显著相关。这些发现表明，硬化素可能作为监测甲状腺功能障碍时骨骼健康的潜在生物标志物。需要进一步的大规模纵向研究来证实其诊断和预后效用。
